State-of-the-art of minimally invasive treatments of bone metastases.

J Bone Oncol · Jun 2022 · Review

Li C, Wu Q, Chang D, Liang H, Ding X, Lao C, et al.

Department of Orthopaedics, The First People's Hospital of Nanning, Nanning, PR China

Orthopaedic Oncology

SUMMARY — THE REDUCTIONMinimally invasive interventional procedures treat bone metastases with less trauma than open surgery; advances in technology expand treatment options beyond conservative care.
Abstract, as published

Bone metastases is a common manifestation of advanced malignant tumors. With the recent advances in medical technology, the survival period of patients with malignant tumors is prolonged, and the probability of bone metastases is significantly increased. Approximately 70% to 80% of patients with breast or prostate cancer will eventually develop bone metastases. In addition, thyroid, lung, and kidney carcinomas are all known to cause bone metastases, with a 30% to 40% incidence upon postmortem assessment. Bone metastases often lead to severe pain, pathological fractures, and nerve damage and have become a critical factor affecting the quality of life and life expectancy of cancer patients. Although treatments for bone metastases are diverse, choosing the appropriate treatment is difficult. Both conservative treatment and open surgery have certain drawbacks and may not be appropriate for all patients. Interventional procedures have the advantages of less trauma with quicker recovery and represent a viable alternative. This review provides updates on the progress of research on the interventional treatment of bone metastases and directions regarding relevant further studies.

Featured in the 2026-06-28 issue.

← Overexpression of lncRNA UCA1 promotes osteosarcoma progressi…Liposarcoma: Molecular Genetics and Therapeutics →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.